Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Buy
63
PBE Quote, Financials, Valuation and Earnings
Last price:
$66.89
Seasonality move
:
2.13%
Day range:
$66.14 - $66.79
52-week range:
$54.52 - $72.84
Dividend yield:
0.25%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
3.1K
Avg. volume:
6K
1-year change:
-2.6%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
$66.14 | -- | -- | -- | $0.13 | 0.25% | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
$166.58 | -- | -- | -- | $1.17 | 0.7% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$82.48 | -- | -- | -- | $0.27 | 1.17% | -- |
|
XBI
SPDR S&P Biotech ETF
|
$87.02 | -- | -- | -- | $0.01 | 0.04% | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
$79.95 | -- | -- | -- | $0.02 | 0.07% | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
$42.08 | -- | -- | -- | $0.10 | 1.42% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.915 | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | 0.653 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.248 | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | 1.018 | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | 1.330 | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | 0.358 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
Invesco Biotechnology & Genome ETF vs. Competitors
-
Which has Higher Returns PBE or FBT?
First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- -
What do Analysts Say About PBE or FBT?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe Invesco Biotechnology & Genome ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 FBTFirst Trust NYSE Arca Biotechnology Index Fund0 0 0 -
Is PBE or FBT More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.810, which suggesting that the stock is 19.007% less volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.641, suggesting its less volatile than the S&P 500 by 35.874%.
-
Which is a Better Dividend Stock PBE or FBT?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.13 per share corresponding to a yield of 0.25%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0.7% to investors and pays a quarterly dividend of $1.17 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or FBT?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- --
-
Which has Higher Returns PBE or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PBE or PJP?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is PBE or PJP More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.810, which suggesting that the stock is 19.007% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.502, suggesting its less volatile than the S&P 500 by 49.771%.
-
Which is a Better Dividend Stock PBE or PJP?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.13 per share corresponding to a yield of 0.25%. Invesco Pharmaceuticals ETF offers a yield of 1.17% to investors and pays a quarterly dividend of $0.27 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or PJP?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns PBE or XBI?
SPDR S&P Biotech ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XBISPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About PBE or XBI?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than SPDR S&P Biotech ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XBISPDR S&P Biotech ETF0 0 0 -
Is PBE or XBI More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.810, which suggesting that the stock is 19.007% less volatile than S&P 500. In comparison SPDR S&P Biotech ETF has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.345%.
-
Which is a Better Dividend Stock PBE or XBI?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.13 per share corresponding to a yield of 0.25%. SPDR S&P Biotech ETF offers a yield of 0.04% to investors and pays a quarterly dividend of $0.01 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XBI?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than SPDR S&P Biotech ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than SPDR S&P Biotech ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XBISPDR S&P Biotech ETF-- -- -- --
-
Which has Higher Returns PBE or XHE?
SPDR S&P Health Care Equipment ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat SPDR S&P Health Care Equipment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XHESPDR S&P Health Care Equipment ETF-- -- -- -
What do Analysts Say About PBE or XHE?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than SPDR S&P Health Care Equipment ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than SPDR S&P Health Care Equipment ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XHESPDR S&P Health Care Equipment ETF0 0 0 -
Is PBE or XHE More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.810, which suggesting that the stock is 19.007% less volatile than S&P 500. In comparison SPDR S&P Health Care Equipment ETF has a beta of 1.047, suggesting its more volatile than the S&P 500 by 4.673%.
-
Which is a Better Dividend Stock PBE or XHE?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.13 per share corresponding to a yield of 0.25%. SPDR S&P Health Care Equipment ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.02 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XHE?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Equipment ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than SPDR S&P Health Care Equipment ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XHESPDR S&P Health Care Equipment ETF-- -- -- --
-
Which has Higher Returns PBE or XPH?
SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PBE or XPH?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than SPDR S&P Pharmaceuticals ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XPHSPDR S&P Pharmaceuticals ETF0 0 0 -
Is PBE or XPH More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.810, which suggesting that the stock is 19.007% less volatile than S&P 500. In comparison SPDR S&P Pharmaceuticals ETF has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.686%.
-
Which is a Better Dividend Stock PBE or XPH?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.13 per share corresponding to a yield of 0.25%. SPDR S&P Pharmaceuticals ETF offers a yield of 1.42% to investors and pays a quarterly dividend of $0.10 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XPH?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Is Roku Stock Undervalued Now?
At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
58
INKT alert for Jul 14
MiNK Therapeutics [INKT] is down 36.03% over the past day.
Buy
51
NEGG alert for Jul 14
Newegg Commerce [NEGG] is down 26.42% over the past day.
Buy
68
ATRO alert for Jul 14
Astronics [ATRO] is down 1.02% over the past day.
